TP53 and acute myeloid leukemia: Functional studies demonstrated that Kmt2d deficiency together with Trp53 and Nf1 loss in hematopoietic stem and progenitor cells could promote AML in recipient mice, supporting that KMT2D is a tumor suppressor in TP53−/− AML.